BLRX Stock Overview
A commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
BioLineRx Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.10 |
| 52 Week High | ₪1.44 |
| 52 Week Low | ₪0.082 |
| Beta | 1.02 |
| 1 Month Change | -50.00% |
| 3 Month Change | -77.45% |
| 1 Year Change | -92.70% |
| 3 Year Change | -94.42% |
| 5 Year Change | -95.77% |
| Change since IPO | -99.88% |
Recent News & Updates
Recent updates
BioLineRx stock slips on $15M securities offering
Sep 19BioLineRx files for FDA approval of motixafortide in stem cell mobilization
Sep 12biolinerx GAAP EPS of -$0.01 beats by $0.08
Aug 16BioLineRx, GenFleet to co-develop Motixafortide treatment for a type of pancreatic cancer
Jun 29BioLineRx: A Top Candidate For A Takeover Before 2022 Ends
Jun 30biolinerx EPS beats by $0.17
May 26BioLineRx (BLRX) shares rocket 73% on positive Motixafortide data in multiple myeloma
May 04BioLineRx jumps 22% on promising triple combination data of motixafortide in pancreatic cancer
Dec 16biolinerx EPS beats by $0.32
Nov 23BioLineRx launches early-stage study with lead asset in COVID-19 related respiratory distress
Nov 18BioLineRx launches mid-stage combo study in first-line pancreatic cancer
Oct 29Shareholder Returns
| BLRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -26.1% | -0.2% | 3.2% |
| 1Y | -92.7% | -7.0% | 24.2% |
Return vs Industry: BLRX underperformed the US Biotechs industry which returned -7% over the past year.
Return vs Market: BLRX underperformed the US Market which returned 24.2% over the past year.
Price Volatility
| BLRX volatility | |
|---|---|
| BLRX Average Weekly Movement | 21.7% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BLRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BLRX's weekly volatility has increased from 15% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 79 | Phil Serlin | www.biolinerx.com |
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions.
BioLineRx Ltd. Fundamentals Summary
| BLRX fundamental statistics | |
|---|---|
| Market cap | US$21.55m |
| Earnings (TTM) | -US$19.92m |
| Revenue (TTM) | US$21.99m |
1.0x
P/S Ratio-1.1x
P/E RatioIs BLRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLRX income statement (TTM) | |
|---|---|
| Revenue | US$21.99m |
| Cost of Revenue | US$6.87m |
| Gross Profit | US$15.13m |
| Other Expenses | US$35.04m |
| Earnings | -US$19.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0093 |
| Gross Margin | 68.78% |
| Net Profit Margin | -90.57% |
| Debt/Equity Ratio | 326.9% |
How did BLRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 10:15 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioLineRx Ltd. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Pantginis | H.C. Wainwright & Co. |
| Michael King | JMP Securities |
| Justin Walsh | JonesTrading Institutional Services, LLC |